Patents by Inventor John A. Kellum
John A. Kellum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240118289Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring hyaluronic acid, death receptor 5, and/or transforming growth factor ?1 can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury.Type: ApplicationFiled: May 22, 2023Publication date: April 11, 2024Inventors: Kai Singbartl, John A. Kellum
-
Publication number: 20240009173Abstract: A method of treating acute kidney injury in a patient is provided, including administering to the patient a 5-HT3-targeting drug, the 5-HT3A-targeting drug, or the pharmaceutically-acceptable salt or solvate of a 5-HT3-targeting drug or a 5-HT3A-targeting drug, in an amount effective to treat acute kidney injury in the patient.Type: ApplicationFiled: November 5, 2021Publication date: January 11, 2024Inventors: LiRong Wang, Xiguang Qi, Xiaojiang Guo, Peihao Fan, John A. Kellum
-
Patent number: 11747342Abstract: A proteomic expression platform to identify age-related sepsis risk is disclosed using patients with an intra-abdominal infection. A semi-quantitative plasma proteomics workflow was applied which incorporated tandem immuno affinity depletion, iTRAQ labeling, strong cation exchange fractionation, and nanoflow-liquid chromatography coupled to high resolution mass spectrometry. A protein profile was determined that exhibit statistically significant differences in expression levels amongst patients with severe sepsis as a function of age. Representative pathways that are differentially-expressed include, but are not limited to, acute phase response, coagulation signaling, atherosclerosis signaling, lipid metabolism, and production of nitric oxide/reactive oxygen species.Type: GrantFiled: February 17, 2021Date of Patent: September 5, 2023Assignee: University Of Pittsburgh—Of The Commonwealth System Of Higher EducationInventors: John A. Kellum, Zhiyun Cao, Derek Angus, Sachin Purushottam Yende, Rena Angilena Sowell Robinson
-
Patent number: 11693014Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring hyaluronic acid, death receptor 5, and/or transforming growth factor ?1 can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury.Type: GrantFiled: January 15, 2020Date of Patent: July 4, 2023Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Kai Singbartl, John A. Kellum, Jr.
-
Publication number: 20220226266Abstract: Provided herein is a method of treating kidney injury associated with trauma or infection, such as in sepsis-associated acute kidney injury.Type: ApplicationFiled: June 1, 2020Publication date: July 21, 2022Inventors: John A. Kellum, Neil Hukriede, Xiaoyan Wen
-
Publication number: 20220143133Abstract: It is an object of the present invention to provide methods and compositions for protection of subjects from acute kidney injury by treating the subject with compounds that modulate the cell cycle. Modulating the cell cycle can comprise inducing G0/G1 cell cycle arrest, and/or inducing cell cycle progression. As demonstrated below, even a single administration of a compound which induces G0/G1 cell cycle arrest can protect subjects from AKI, and may be used prophylactically in advance of, or as a treatment following, various treatments or conditions that are known to be injurious to the kidney, followed optionally by release of the arrest. Once AKI is established, cell cycle progression can be induced to increase replacement of lost and damaged cells.Type: ApplicationFiled: January 24, 2022Publication date: May 12, 2022Applicants: ASTUTE MEDICAL, INC., UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: PAUL MCPHERSON, JOHN A. KELLUM
-
Patent number: 11243217Abstract: The present invention provides methods and compositions for identifying patients at risk of kidney injury. A risk score, which is a composite of a urinary concentration of IGFBP7 (insulin-like growth factor-binding protein 7) and a urinary concentration of TIMP-2 (tissue inhibitor of metalloproteinase 2), is determined obtained from the patient, and is used to manage patient treatment.Type: GrantFiled: June 6, 2017Date of Patent: February 8, 2022Assignees: Astute Medical, Inc., University of Pittsburgh—of the Commonwealth System of Higher EducationInventors: Paul McPherson, James Patrick Kampf, John A. Kellum
-
Patent number: 11243202Abstract: It is an object of the present invention to provide methods for assessing the efficacy of a remote ischemic preconditioning procedure though the measurement of urinary TIMP-2 and IGFBP7 concentrations.Type: GrantFiled: April 8, 2016Date of Patent: February 8, 2022Assignees: ASTUTE MEDICAL, INC., UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, WESTFÄLISCHE WILHELMS-UNIVERSITÄT MÜNSTERInventors: Paul McPherson, John A. Kellum, Jr., Alexander Zarbock
-
Patent number: 11229676Abstract: It is an object of the present invention to provide methods and compositions for protection of subjects from acute kidney injury by treating the subject with compounds that modulate the cell cycle. Modulating the cell cycle can comprise inducing G0/G1 cell cycle arrest, and/or inducing cell cycle progression. As demonstrated below, even a single administration of a compound which induces G0/G1 cell cycle arrest can protect subjects from AKI, and may be used prophylactically in advance of, or as a treatment following, various treatments or conditions that are known to be injurious to the kidney, followed optionally by release of the arrest. Once AKI is established, cell cycle progression can be induced to increase replacement of lost and damaged cells.Type: GrantFiled: May 24, 2019Date of Patent: January 25, 2022Assignee: ASTUTE MEDICAL, INC.Inventors: Paul McPherson, John A. Kellum
-
Publication number: 20210270841Abstract: A proteomic expression platform to identify age-related sepsis risk is disclosed using patients with an intra-abdominal infection. A semi-quantitative plasma proteomics workflow was applied which incorporated tandem immuno affinity depletion, iTRAQ labeling, strong cation exchange fractionation, and nanoflow-liquid chromatography coupled to high resolution mass spectrometry. A protein profile was determined that exhibit statistically significant differences in expression levels amongst patients with severe sepsis as a function of age. Representative pathways that are differentially-expressed include, but are not limited to, acute phase response, coagulation signaling, atherosclerosis signaling, lipid metabolism, and production of nitric oxide/reactive oxygen species.Type: ApplicationFiled: February 17, 2021Publication date: September 2, 2021Inventors: John A. Kellum, Zhiyun Cao, Derek Angus, Sachin Purushottam Yende, Rena Angilena Sowell Robinson
-
Patent number: 10948497Abstract: A proteomic expression platform to identify age-related sepsis risk is disclosed using patients with an intra-abdominal infection. A semi-quantitative plasma proteomics workflow was applied which incorporated tandem immuno affinity depletion, iTRAQ labeling, strong cation exchange fractionation, and nanoflow-liquid chromatography coupled to high resolution mass spectrometry. A protein profile was determined that exhibit statistically significant differences in expression levels amongst patients with severe sepsis as a function of age. Representative pathways that are differentially-expressed include, but are not limited to, acute phase response, coagulation signaling, atherosclerosis signaling, lipid metabolism, and production of nitric oxide/reactive oxygen species.Type: GrantFiled: October 8, 2018Date of Patent: March 16, 2021Assignee: The University of Pittsburgh—the Commonwealth of Higher EducationInventors: John A. Kellum, Zhiyun Cao, Derek Angus, Sachin Purushottam Yende, Rena Angilena Sowell Robinson
-
Publication number: 20200284805Abstract: Disclosed herein are methods of identifying biomarkers (such as genes (e.g., RNA or mRNA), proteins, and/or small molecules) that can be used to predict organ or tissue function or dysfunction. In some embodiments, the methods include ex vivo perfusion of the organ or tissue, collection of samples from the organ or tissue (for example, perfusate, fluids produced by the organ (such as bile or urine), or tissue biopsies) and measuring the level of one or more biomarkers in the sample. It is also disclosed herein that an analysis of biomarkers (such as genes (e.g., RNA or mRNA), proteins, and/or small molecules) present in a biological sample from an organ, tissue, or subject can be used to identify whether the organ, tissue, or subject is at risk for (or has) organ dysfunction or organ failure.Type: ApplicationFiled: March 19, 2020Publication date: September 10, 2020Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Paulo Artur Chaves Fontes, John A. Kellum
-
Publication number: 20200150132Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring hyaluronic acid, death receptor 5, and/or transforming growth factor ?1 can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury.Type: ApplicationFiled: January 15, 2020Publication date: May 14, 2020Inventors: Kai Singbartl, John A. Kellum, JR.
-
Patent number: 10634686Abstract: Disclosed herein are methods of identifying biomarkers (such as genes (e.g., RNA or mRNA), proteins, and/or small molecules) that can be used to predict organ or tissue function or dysfunction. In some embodiments, the methods include ex vivo perfusion of the organ or tissue, collection of samples from the organ or tissue (for example, perfusate, fluids produced by the organ (such as bile or urine), or tissue biopsies) and measuring the level of one or more biomarkers in the sample. It is also disclosed herein that an analysis of biomarkers (such as genes (e.g., RNA or mRNA), proteins, and/or small molecules) present in a biological sample from an organ, tissue, or subject can be used to identify whether the organ, tissue, or subject is at risk for (or has) organ dysfunction or organ failure.Type: GrantFiled: September 23, 2014Date of Patent: April 28, 2020Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Paulo Artur Chaves Fontes, John A. Kellum
-
Patent number: 10557856Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring hyaluronic acid, death receptor 5, and/or transforming growth factor ?1 can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury.Type: GrantFiled: September 16, 2011Date of Patent: February 11, 2020Assignee: University Of Pittsburgh-Of The Commonwealth System Of Higher EducationInventors: Kai Singbartl, John A. Kellum, Jr.
-
Patent number: 10533989Abstract: The present invention describes a global metabolomic profile of patients with community acquired pneumonia (CAP) and sepsis. The metabolomic profile of endogenous small molecules blood was determined using mass-spectrometry. The global metabolomic profile in plasma demonstrated broad differences between CAP and sepsis patients when comparing those who do and do not survive at 90 days. Increases in specific metabolite biomarkers displayed on a heat map provide early diagnosis of these medical conditions to allow for early intervention and aggressive treatment.Type: GrantFiled: June 25, 2013Date of Patent: January 14, 2020Assignee: University Of Pittsburgh—Of The Commonwealth System Of Higher EducationInventors: John A. Kellum, Christopher W. Seymour
-
Publication number: 20190381130Abstract: It is an object of the present invention to provide methods and compositions for protection of subjects from acute kidney injury by treating the subject with compounds that modulate the cell cycle. Modulating the cell cycle can comprise inducing G0/G1 cell cycle arrest, and/or inducing cell cycle progression. As demonstrated below, even a single administration of a compound which induces G0/G1 cell cycle arrest can protect subjects from AKI, and may be used prophylactically in advance of, or as a treatment following, various treatments or conditions that are known to be injurious to the kidney, followed optionally by release of the arrest. Once AKI is established, cell cycle progression can be induced to increase replacement of lost and damaged cells.Type: ApplicationFiled: May 24, 2019Publication date: December 19, 2019Applicants: ASTUTE MEDICAL, INC., THE UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: PAUL MCPHERSON, JOHN A. KELLUM
-
Publication number: 20190302131Abstract: The present invention provides methods and compositions for identifying patients at risk of kidney injury. A risk score, which is a composite of a urinary concentration of IGFBP7 (insulin-like growth factor-binding protein 7) and a urinary concentration of TIMP-2 (tissue inhibitor of metalloproteinase 2), is determined obtained from the patient, and is used to manage patient treatment.Type: ApplicationFiled: June 6, 2017Publication date: October 3, 2019Applicants: ASTUTE MEDICAL, INC., UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: PAUL MCPHERSON, JAMES PATRICK KAMPF, JOHN A. KELLUM
-
Publication number: 20190265251Abstract: A proteomic expression platform to identify age-related sepsis risk is disclosed using patients with an intra-abdominal infection. A semi-quantitative plasma proteomics workflow was applied which incorporated tandem immuno affinity depletion, iTRAQ labeling, strong cation exchange fractionation, and nanoflow-liquid chromatography coupled to high resolution mass spectrometry. A protein profile was determined that exhibit statistically significant differences in expression levels amongst patients with severe sepsis as a function of age. Representative pathways that are differentially-expressed include, but are not limited to, acute phase response, coagulation signaling, atherosclerosis signaling, lipid metabolism, and production of nitric oxide/reactive oxygen species.Type: ApplicationFiled: October 8, 2018Publication date: August 29, 2019Inventors: John A. Kellum, Zhiyun Cao, Derek Angus, Sachin Purushottam Yende, Rena Angilena Sowell Robinson
-
Publication number: 20190263926Abstract: The invention provides methods for the treatment of subjects having or at risk of having kidney injuries using antibodies that specifically bind Metalloproteinase inhibitor 2 (TIMP-2). Specifically, the methods can be used for the treatment of a subject having chronic kidney disease (CKD), acute kidney injury (AKI), or a subject having an existing diagnosis of one or more of congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, glomerular filtration below the normal range, cirrhosis, serum creatinine above the normal range, sepsis, or acute renal failure (ARP).Type: ApplicationFiled: October 27, 2017Publication date: August 29, 2019Applicants: ASTUTE MEDICAL, INC., UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: PAUL MCPHERSON, JOHN A. KELLUM